<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03206138</url>
  </required_header>
  <id_info>
    <org_study_id>GX-188E_GX-I7_IMQ_CIN3</org_study_id>
    <nct_id>NCT03206138</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of GX-188E Administered Via EP Plus GX-I7 or Imiquimod.</brief_title>
  <official_title>A Randomized, Open-label Study to Evaluate the Safety and Efficacy of GX-188E, a DNA Therapeutic Vaccine Administered Intramuscularly by Electroporation, With GX-I7 Intravaginal Application or Imiquimod Topical Application in HPV16 and/or 18 Positive Patients With CIN3.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul St. Mary's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genexine, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul St. Mary's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to investigate the safety and efficacy of GX-188E administered IM plus local
      administration of GX-I7 or Imiquimod at cervix in subjects with cervical intraepithelial
      neoplasia (CIN) 3.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 30, 2017</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ratio of subjects who have histopathological regression of cervical lesions to CIN 1 or less in HPV 16 or 18-associated CIN3 subjects.</measure>
    <time_frame>at week 20</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ratio of subjects with clearance of HPV 16 or 18 and histopathological regression of cervical lesions to CIN 1 or less.</measure>
    <time_frame>at week 20, and week 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of cytology of uterine cervix compared to baseline.</measure>
    <time_frame>at screening, week 12, week 20, and week 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Flt-3L concentrations in blood samples.</measure>
    <time_frame>at week 14, week 20, and week 36.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Cervical Intraepithelial Neoplasia 3</condition>
  <arm_group>
    <arm_group_label>GX-188E, GX-I7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GX-188E + GX-I7</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GX-188E, Imiquimod</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GX-188E + Imiquimod</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GX-188E, GX-I7</intervention_name>
    <description>Experimental: 1mg of GX-188E administered IM using EP device 3 times and 3mg of GX-I7 administered in cervix 4 times.</description>
    <arm_group_label>GX-188E, GX-I7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GX-188E, Imiquimod</intervention_name>
    <description>1mg of GX-188E administered IM using EP device 3 times and 12.5mg of Imiquimod application at cervix 8 times.</description>
    <arm_group_label>GX-188E, Imiquimod</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able and willing to comply with all study procedures and voluntarily signs informed
             consent form.

          -  Female subjects age 19-50 years.

          -  HPV 16 and/or 18 positive.

          -  Colposcopy is satisfactory based on visualization of the entire squamocolumnar
             junction and the upper limit of the entire aceto-white or suspected CIN disease area

          -  Histopathologically diagnosed with Cervical Intraepithelial Neoplasia 3, CIN 3.

        Exclusion Criteria:

          -  Pregnancy or breastfeeding

          -  History of previous therapeutic HPV vaccination (individuals who have been immunized
             with licensed prophylactic HPV vaccines are not excluded).

          -  Positive serological test for hepatitis C virus or hepatitis B virus surface antigen
             (HBsAg) or human immunodeficiency virus (HIV).

          -  Any other ineligible condition at the discretion of the investigator that would be
             ineligible to participate the study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jong-Sup Park</last_name>
    <phone>+82-2-2258-2724</phone>
    <email>jspark@catholic.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul St. Mary's hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Genexine</last_name>
      <phone>031-628-3271</phone>
      <phone_ext>82</phone_ext>
      <email>yyhwang@genexine.com</email>
    </contact>
    <investigator>
      <last_name>Jong-Sup Park, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tae-Jin Kim, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jae-Kwan Lee, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Young Tae Kim, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chi-Heum Cho, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2017</study_first_submitted>
  <study_first_submitted_qc>June 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2017</study_first_posted>
  <last_update_submitted>June 29, 2017</last_update_submitted>
  <last_update_submitted_qc>June 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul St. Mary's Hospital</investigator_affiliation>
    <investigator_full_name>Jongsup Park</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Investigator trial</keyword>
  <keyword>Cervical Intraepithelial Neoplasia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imiquimod</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

